Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Changes in Ganglioside Antibody Positivity Rates During the COVID-19 Pandemic

Changes in ganglioside antibody positivity rates during the COVID-19 pandemic

Authors: Racke MK, Niles JK, Lorenz RA, Kaufman HW.

Citation: J. Neuroimmunol. 2022 Jun 15; 367: 577877. Online ahead of print 2022 Apr 22. doi: 10.1016/j.jneuroim.2022.577877.

Specialties: Infectious Disease, Neurology, COVID-19

Download key summary

Related content

Conference Presentation
Changes in Guillain-Barre Syndrome-Associated Ganglioside Antibody Test Results at a National Clinical Laboratory During the COVID-19 Pandemic
Publication
Current State of Pediatric Reference Intervals and the Importance of Correctly Describing the Biochemistry of Child Development: A Review
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
Publication
New Cancer Diagnoses Still Lagging in the United States in Second Full Year of COVID-19 Pandemic
Publication
New diagnosis of systemic lupus erythematosus after COVID-19 vaccination: A case report and review of literature

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.